Polycystic ovary syndrome and epilepsy: A review of the evidence

Drugs

Volumn 63, Issue 12, 2003, Pages 1185-1227

  Meo, Roberta ^a,c   Bilo, Leonilda ^b  

^a ASL NA 4   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; LITHIUM; OXCARBAZEPINE; PHENOBARBITAL; PRIMIDONE; VALPROIC ACID;

AMENORRHEA; ANTICONVULSANT THERAPY; BODY WEIGHT; CARDIOVASCULAR RISK; CONSULTATION; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; DISEASE COURSE; EPILEPSY; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERINSULINISM; HYPOTHALAMUS; HYPOTHESIS; INSULIN RESISTANCE; MEDICAL LITERATURE; MEDICAL RESEARCH; MENORRHAGIA; METHODOLOGY; NONHUMAN; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; PARAMETER; PRACTICE GUIDELINE; PROSPECTIVE STUDY; REPRODUCTION; REVIEW; RISK;

ADOLESCENT; ADULT; ANTICONVULSANTS; CLINICAL TRIALS; EPILEPSY; FEMALE; HUMANS; MENSTRUATION DISTURBANCES; POLYCYSTIC OVARY SYNDROME; PREVALENCE; VALPROIC ACID;

FALLOPIA;

EID: 0038575815     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363120-00002     Document Type: Review

References (168)

1. Herzog AG, Seibel MM, Schomer D, et al. Temporal lobe epilepsy: an extrahypothalamic pathogenesis for polycystic ovary syndrome? Neurology 1984; 34: 1389-93
2. Herzog AG, Seibel MM, Schomer D, et al. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 1986; 43: 341-6
3. Bilo L, Meo R, Nappi C, et al. Reproductive endocrine disorders in women with primary generalized epilepsy. Epilepsia 1988; 29: 612-9
4. Herzog AG. A hypothesis to integrate partial seizures of temporal lobe origin and reproductive endocrine disorders. Epilepsy Res 1989; 3: 151-9
5. Nappi C, Meo R, Di Carlo C, et al. Reduced fertility and neuroendocrine dysfunction in women with epilepsy. Gynecol Endocrinol 1994; 8: 133-45
6. Herzog AG. Temporolimbic epilepsy and polycystic ovary syndrome. Fertil Steril 1996; 65 (1): 210-1
7. Isojarvi JIT, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993; 329: 1383-8
8. Isojarvi JIT, Laatikainen TJ, Knip M, et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996; 39 (5): 579-84
9. Isojarvi JIT, Tauboll E, Olav Dale P, et al. Polycystic ovaries in women taking valproate monotherapy for epilepsy: a two-center study [abstract]. Epilepsia 1997; 38 Suppl. 8: 102
10. Isojarvi JIT, Rattya J, Knip M, et al. Replacing valproate with lamotrigine reduces cardiovascular risks and insulin mediated hyperandrogenism in women with epilepsy [abstract]. Epilepsia 1997; 38 Suppl. 3: 279
11. Isojarvi JIT, Rattya J, Myllyla VV, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998; 43: 446-51
12. Pylvanen V, Pakarinen AJ, Knip M, et al. Serum insulin and leptin levels in valproate-related obesity [abstract]. Epilepsia 1998; 39 Suppl. 6: 128
13. Rattya J, Vainionpaa L, Knip M, et al. Growth and pubertal maturation in girls with epilepsy [abstract]. Epilepsia 1998; 39 Suppl. 6: 155
14. Vainionpaa L, Rattya J, Knip M, et al. Hyperandrogenism in girls aged 8-18 years taking valproate [abstract]. Epilepsia 1998; 39 Suppl. 6: 162
15. Isojarvi JIT, Tauboll E, Pakarinen AJ, et al. Valproate-related endocrine risks in women with epilepsy: a multicenter study [abstract]. Epilepsia 1998; 39 Suppl. 6: 220-1
16. Rattya J, Vainonpaa L, Knip M, et al. The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 1999; 103: 588-93
17. Vainonpaa L, Rattya J, Knip M, et al. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol 1999; 45: 444-50
18. Isojarvi JIT, Tolonen U, Ansakorpi H, et al. Polycystic ovaries and hyperandrogenism in women with epilepsy [abstract]. Epilepsia 1999; 40 Suppl. 2: 194
19. Isojarvi JIT, Tapanainen J. Valproate, hyperandrogenism, and polycystic ovaries: a report of 3 cases. Arch Neurol 2000; 57: 1064-8
20. Rattya J, Pakarinen AJ, Knip M, et al. Early hormonal changes during valproate or carbamazepine treatment. Neurology 2001; 57: 440-4
21. Isojarvi JIT, Tauboll E, Pakarinen AJ, et al. Altered ovarian function and cardiovascular risk factors in valproate-treated women. Am J Med 2001; 111: 290-6
22. Lofgren E, Tapanainen J, Pakarinen AJ, et al. Effects of oxcarbazepine and sodium valproate on reproductive function in women with epilepsy [abstract]. Epilepsia 2001; 42 Suppl. 7: 292
23. Isojarvi JIT, Pakarinen AJ, Tapanainen J. Reproductive endocrine function in women after starting valproate for epilepsy [abstract]. Epilepsia 2001; 42 Suppl. 7: 291
24. Isojarvi JIT, Morrell M, O'Neill F, et al. Cross-sectional study comparing weight gain and androgen levels in women with epilepsy taking lamotrigine or valproate monotherapy [abstract]. Epilepsia 2001; 42 Suppl. 2: 147
25. Pylvanen V, Knip M, Pakarinen AJ, et al. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia 2002; 43 (5): 514-7
26. Bodenstener J. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Clin Pediatr 1999; 38 (11): 681-3
27. Garland E, Behr R. Hormonal effects of valproic acid? J Am Acad Child Adolesc Psychiatry 1996; 35 (11): 1424-5
28. Geller B. Reply BPD and ADHD [letter]. J Am Acad Child Adolesc Psychiatry 1997; 36: 720
29. Johnston H, Witkovsky M, Fruehling J. Valproate, ovaries and teenage girls. Just The Facts 1997; 4: 1-2
30. Eberle A. Valproate and polycystic ovaries [letter]. J Am Acad Child Adolesc Psychiatry 1998; 37: 1009
31. Irwin M, Masand P. Valproate and polycystic ovaries [letter]. J Am Acad Child Adolesc Psychiatry 1998; 37: 9-10
32. Geller B. Reply valproate and polycystic ovaries [letter]. J Am Acad Child Adolesc Psychiatry 1998; 37: 9-10
33. Johnston H. More on valproate and polycystic ovaries [letter]. J Am Acad Child Adolesc Psychiatry 1999; 38: 354
34. Piontek C, Wisner K. Appropriate clinical management of women taking valproate. J Clin Psychiatry 2000; 61 (3): 161-3
35. Soares J. Valproate treatment and the risk of hyperandrogenism and polycystic ovaries. Bipolar Disord 2000; 2: 37-41
36. Gracious B, Wisner K. Valproate and the risk of hyperandrogenism. Bipolar Disord 2001; 3 (1): 50-1
37. Soares J. Reply to Drs Gracious and Wisner: valproate, hyperandrogenism, and polycystic ovaries [letter]. Bipolar Disord 2001; 3: 51
38. Ernst C, Goldberg J. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry 2002; 63 Suppl. 4: 42-55
39. Morrell M. Maximizing the health of women with epilepsy: science and ethics in new drug development. Epilepsia 1997; 38 Suppl. 4: S32-41
40. Morrell M. Effects of epilepsy on women's reproductive health. Epilepsia 1998; 39 Suppl. 8: S32-7
41. Morrell M. Guidelines for the care of women with epilepsy. Neurology 1998; 51 Suppl. 4: S21-7
42. Zahn C, Morrell M, Collins S, et al. Management issues for women with epilepsy: a review of the literature. Neurology 1998; 51 (4): 949-56
43. Morrell M. Epilepsy in women: the science of why it is special. Neurology 1999; 53 Suppl. 1: S42-8
44. Dansky LV. Fertility in men and women with epilepsy [abstract]. Epilepsia 1997; 38 Suppl. 3: 52
45. Morrell M. Effects of reproductive hormones on epilepsy: a clinical overview [abstract]. Epilepsia 1998; 39 (6): 210
46. Genton P, Bauer G, Elger C. Valproate and polycystic ovaries: is it really an issue? [abstract]. Epilepsia 1999; 40 Suppl. 2: 295
47. Herzog AG. Polycystic ovarian syndrome in women with epilepsy: epileptic or iatrogenic? Ann Neurol 1996; 39 (5): 559-60
48. Duncan S. Polycystic ovarian syndrome in women with epilepsy. Aspects of Epilepsy 1998; 9: 1-6
49. Chappell K, Markowitz J, Jackson C. Is valproate pharmacotherapy associated with polycystic ovaries? Ann Pharmacother 1999; 33 (11): 1211-6
50. Balen A, Genton P. Valproate for girls with epilepsy. Ann Neurol 2000; 47: 550-1
51. Reuber M, Goulding P. Valproate, the polycystic ovary syndrome and the need for a prospective study. Seizure 2000; 9: 235-6
52. Bauer J. Epilepsy therapy: issues for women and men. Curr Opin Neurol 2001; 14: 199-202
53. Betts T, Dutton N, Yarrow H. Epilepsy and the ovary (cutting out the hysteria). Seizure 2001; 10 (3): 220-8
54. Betts T. Case reports. Seizure 2001; 10 (3): 229-34
55. Duncan S. Polycystic ovarian syndrome in women with epilepsy: a review. Epilepsia 2001; 42 Suppl. 3: 60-5
56. Genton P, Bauer J, Duncan S, et al. On the association between valproate and polycystic ovary syndrome. Epilepsia 2001; 42 (3): 295-304
57. Herzog AG, Schachter S. Valproate and the polycystic ovary syndrome: final thoughts. Epilepsia 2001; 42 (3): 311-5
58. Isojarvi JIT, Tauboll E, Tapanainen J, et al. On the association between valproate and polycystic ovary syndrome: a response and an alternative view. Epilepsia 2001; 42: 305-10
59. Isojarvi JIT, Vainonpaa L, Knip M, et al. Reply [letter]. Ann Neurol 2001; 47: 551-2
60. Joffe H, Taylor AE, Hall JE. Polycystic ovarian syndrome: relationship to epilepsy and antiepileptic drug therapy. J Clin Endocrinol Metab 2001; 86 (7): 2946-9
61. Bauer J, Isojarvi JIT, Herzog AG, et al. Reproductive dysfunction in women with epilepsy: recommendations for evaluation and management. J Neurol Neurosurg Psychiatry 2002; 73: 121-5
62. Morrell M, Springer E, Giudice L. Reproductive function in women with epilepsy on inducing and noninducing antiepileptic drugs [abstract]. Epilepsia 1997; 38 Suppl. 8: 232
63. Murialdo G, Galimberti CA, Magri F, et al. Menstrual cycle and ovary alterations in women with epilepsy on antiepileptic therapy. J Endocrinol Invest 1997; 20: 519-26
64. Toidze O, Kasradze S. Epilepsy and polycystic ovarian syndrome at pre-adolescent and puberty period [abstract]. Epilepsia 1997; 38 Suppl. 3: 270
65. Kasradze S, Toidze O, Sturua L. Polycystic ovarian syndrome and menstrual cycle disturbances in women with epilepsy [abstract]. Epilepsia 1998; 39 Suppl. 2: 87
66. Murialdo G, Galimberti CA, Gianelli MV, et al. Effects of valproate, phenobarbital, and carbamazepine on sex steroid setup in women with epilepsy. Clin Neuropharmacol 1998; 21 (1): 52-8
67. Bauer J, Sommerburger J, Klingmuller D, et al. Polycystic ovarian syndrome (PCOS) in female patients with medically treated epilepsy exhibiting weight gain [abstract]. Epilepsia 1999; 40 Suppl. 2: 277
68. Abraham I, Lechleitner M, Windisch J, et al. Antiepileptic drugs, obesity and polycystic ovaries [abstract]. Epilepsia 2000; 41: 53-4
69. Bauer J, Jarre A, Klingmuller D, et al. Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women. Epilepsy Res 2000; 41: 163-7
70. Betts T, Yarrow H. Ovarian structure and function in women taking valproate or lamotrigine in monotherapy [abstract]. Epilepsia 2000; 41: 143
71. Khatami R, Henrich W, Bauer M, et al. The significance of polycystic ovaries in women with epilepsy under treatment with antiepileptic drugs: preliminary results of a prospective observational study [abstract]. Epilepsia 2000; 41: 143
72. Stephen L, Kwan P, Shapiro D, et al. Hormone profiles in patients only ever treated with sodium valproate or lamotrigine [abstract]. Epilepsia 2000; 41: 111
73. Betts T, Yarrow H, Greenhill L, et al. A comparison of the structure and function of ovaries in a group of women without epilepsy and in groups of women with epilepsy who have only ever taken either valproate, lamotrigine or carbamazepine [abstract]. Epilepsia 2001; 42 Suppl. 7: 297-8
74. Luef G, Abraham I, Trinka E, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001; 57 (3): 565-6
75. Luef G, Abraham I, Haslinger M, et al. Polycystic ovaries, obesity and insulin resistance in women with epilepsy: a comparative study of carbamazepine and valproate in 105 women [abstract]. Epilepsia 2001; 42 Suppl. 2: 88
76. Morrell M, Flynn K, Done S, et al. Ovulatory failure is most common in women with primary generalized epilepsy treated with valproate [abstract]. Epilepsia 2001; 42 Suppl. 7: 296-7
77. Stephen L, Kwan P, Shapiro D, et al. Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy. Epilepsia 2001; 42 (8): 1002-6
78. Stephen L, Kwan P, Shapiro D, et al. Hormones in adults under 50 years treated with sodium valproate or lamotrigine monotherapy [abstract]. Epilepsia 2001; 42 Suppl. 2: 36
79. Luef G, Abraham I, Trinka E, et al. Hyperandrogenism, post-prandial hyperinsulinism and the risk of PCOS in a cross sectional study of women with epilepsy treated with valproate. Epilepsy Res 2002; 48: 91-102
80. Luef G, Abraham I, Haslinger M, et al. Polycystic ovaries, obesity and insulin resistance in women with epilepsy: a comparative study of carbamazepine and valproic acid in 105 women. J Neurol 2002; 249: 835-41
81. Chakravarty A. Preliminary observations on valproate and cystic ovaries. Neurology India 2002; 50: 106-7
82. O'Donovan C, Graves J, Kusumakar V. Prevalence rates of self-reported menstrual abnormalities and clinical hyperandrogenism of women taking divalproex for bipolar mood disorder [abstract no. 89]. Proceedings of the Third Conference on Bipolar Disorder; 1999 Jun 17-19; Pittsburgh (PA)
83. Rasgon N, Altshuler L, Guideman D, et al. Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report. J Clin Psychiatry 2000; 61: 173-8
84. McIntyre R, Mancini D, McCann S, et al. Reproductive and metabolic risks of divalproex in bipolar females [abstract no. NR105]. Proceedings of the Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans (LA)
85. O'Donovan C, Kusumakar V, Graves G, et al. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J Clin Psychiatry 2002; 63: 322-30
86. Lobo RA. A disorder without identity: 'HCA', 'PCO', 'PCOD', 'PCOS', 'SLS'. What are we to call it? Fertil Steril 1995; 63 (6): 1158-60
87. Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev 1995; 16: 322-53
88. Taylor AE. Polycystic ovary syndrome. Endocrinol Metab Clin North Am 1998; 27 (4): 877-902
89. Lakhani K, Seifalian A, Atiomo W, et al. Polycystic ovaries. Br J Radiol 2002; 75 (889): 9-16
90. Clayton RN, Ogden V, Hodginson J, et al. How common are polycystic ovaries in normal women and what is their significance for the fertility of the population? Clin Endocrinol 1992; 37: 127-34
91. Zawadzki J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A. Givens J, Haseltine F, et al., editors. Polycystic ovary syndrome. Boston (MA): Blackwell Scientific, 1992: 152-60
92. Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. BMJ 1986; 293: 355-9
93. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83: 3078-82
94. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999; 84: 4006-11
95. Asuncion M, Calvo RM, San Millan JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85: 2434-8
96. Herzog AG. Neurologic considerations. In: Seibel MM, editor. Infertility: a comprehensive text. Norwalk (CT): Appleton & Lange, 1991: 249-57
97. Hall JE. Polycystic ovarian disease as a neuroendocrine disorder of the female reproductive axis. Endocrinol Metab Clin North Am 1993; 22: 75-92
98. Rosenfield RL. Is polycycstic ovary syndrome a neuroendocrine or an ovarian disorder? Clin Endocrinol 1997; 47: 423-4
99. Yen S. Polycystic ovary syndrome. In: Yen S, Jaffe R, Barbieri R, editors. Hyperandrogenic chronic anovulation. Philadelphia (PA): WB Saunders, 1999: 436-78
100. Dana-Haeri J, Trimble M, Oxley J. Prolactin and gonadotropin changes following generalised and partial seizures. J Neurol Neurosurg Psychiatry 1983; 46: 331-5
101. Dana-Haeri J, Trimble MR. Prolactin and gonadotropin changes following partial seizures in epileptic patients with and without psychopathology. Biol Psychiatry 1984; 19: 329-36
102. Mattson RH, Toftness BR, Cramer JA. Postictal pituitary hormonal changes [abstract]. Neurology 1987; 37 Suppl. 1: 100-1
103. Edwards H, MacLusky N, Burnham W. Epileptic seizures: do they cause reproductive dysfunction? Univ Toronto Med J 2000; 77 (2): 104-11
104. Bhanot R, Wilkinson M. Repeated convulsions induce pseudopregnancy in the intact rat and inhibit steorid-mediated gonadotropin secretion in the ovariectomized rat. J Endocrinol 1983; 95: 43-8
105. Amado D, Verreschi I, Berzaghi M. et al. Effects of intrahippocampal injection of kainic acid on estrous cycle in rats. Braz J Med Biol Res 1987; 20: 829-32
106. Amado D, Cavalheiro EA. Hormonal and gestational parameters in female rats submitted to pilocarpine model of epilepsy. Epilepsy Res 1998; 32: 266-74
107. Renaud LP. Influence of amygdala stimulation on the activity of identified tuberinfundibular neurons in the rat hypothalamus. J Physiol 1976; 260: 237-52
108. Dreifuss J, Murphy J, Gloor P. Contrasting effects of two identified amygdaloid efferent pathways on single hypothalamic neurons. J Neurophysiol 1986; 31: 237-48
109. Edwards H, Burnham W, Ng M, et al. Limbic seizures alter reproductive function in the female rat. Epilepsia 1999; 40 (10): 1370-7
110. Carson R, Wilkinson M. Seizure-induced delay of puberty in female rats: effect of age, stress and opioid antagonists. J Endocrinol 1989; 121: 32-9
111. Bhanot R, Wilkinson M. Differential effects of fluorothyl- and electro-convulsive shock on sexual maturation and prolactin release in the rat. Exp Brain Res 1984; 5: 32-9
112. Amado D, Cavalheiro EA, Bentivoglio M. Epilepsy and hormonal regulation: the patterns of GnRH and galanin immunoreactivity in the hypothalamus of epileptic female rats. Epilepsy Res 1993; 14: 149-59
113. Bilo L, Meo R, Valentino R, et al. Abnormal pattern of Luteinizing Hormone pulsatility in women with epilepsy. Fertil Steril 1991; 55: 705-11
114. Drislane FW, Coleman AE, Schomer DL, et al. Altered pulsatile secretion of luteinizing hormone in women with epilepsy. Neurology 1994; 44: 306-10
115. Morrell M, Seale C, Hamdy S, et al. Luteinizing hormone pulsatility in women with epilepsy treated with AED monotherapy [abstract]. Epilepsia 1998; 39 Suppl. 6: 221
116. Morrell M, Sauer M, Giudice L, et al. Pituitary gonadotropin function in women with epilepsy [abstract]. Epilepsia 2000; 41 Suppl. 7: 247
117. Quigg M, Kiely J, Shneker B, et al. Chronic elevation of pulsatile luteinizing hormone secretion and acute depression of postictal pulse rate and orderliness in temporal lobe epilepsy [abstract]. Epilepsia 2001; 42 Suppl. 7: 118-9
118. Meo R, Bilo L, Nappi C, et al. Derangement of the hypothalamic GnRH pulse generator in women with epilepsy. Seizure 1993; 2: 241-52
119. Meo R, Bilo L, Valentino R, et al. Reproductive endocrine diseases in women with epilepsy: relations to epilepsy type, antiepileptic therapy, and ovulation dynamics [abstract]. Epilepsia 1997; 38 Suppl. 8: 232
120. Bilo L, Meo R, Valentino R, et al. Characterization of reproductive endocrine disorders in women with epilepsy. J Clin Endocrinol Metab 2001; 86 (7): 2950-6
121. Gloor P, Pellegrini A, Kostopoulos GK. Effects of changes in cortical excitability upon the epileptic bursts in generalized penicillin epilepsy of the cat. Electroencephalogr Clin Neurophysiol 1979; 46: 274-89
122. Quesney LF, Andermann F, Lal S, et al. Transient abolition of generalized photosensitive epileptic discharge in humans by apomorphine, a dopamine receptor agonist. Neurology 1980; 30: 1169-74
123. Van Gelder NM, Janjua NA, Metrakos K, et al. Plasma aminoacids in 3 per second spike-wave epilepsy. Neurochem Res 1980; 5: 661-73
124. Quesney LF, Andermann F, Gloor P. Dopaminergic mechanism in generalized photosensitive epilepsy. Neurology 1981; 31: 1542-4
125. Janjua NA, Metrakos JD, Van Gelder NM. Plasma amino acids in epilepsy. In: Anderson VE, Hauser WA, Penry JK, et al., editors. Genetic basis of the epilepsies. New York: Raven Press, 1982: 181-97
126. Van Gelder NM, Siatitsis I, Menini C, et al. Feline generalized penicillin epilepsy: changes of glutamic acid and taurine parallel the progressive increase in excitability of the cortex. Epilepsia 1983; 24: 200-13
127. Myslobodsky MS. Petit mal epilepsy: too little or too much GABA? In: Fariello AG, Morselli PL, Lloyd KG, et al., editors. Neurotransmitters, seizures and epilepsy. New York: Raven Press, 1984: 337-46
128. Lee RJ, McCabe RT, Wamsley JK, et al. Opioid receptor alterations in a genetic model of generalized epilepsy. Brain Res 1986; 380: 76-82
129. Sackellares J, Crosby C. Long-term efficacy of valproic acid (VPA) in the treatment of absence seizures. Neurology 1980; 30: 420
130. Margraf JW, Dreifuss FE. Amenorrhea following initiation of therapy with valproic acid [abstract]. Neurology 1981; 31: 151
131. de Krom MCTFM, Hoppener RJEA, Beukers E. Adverse reactions of sodium valproate: secondary amenorrhea and weight gain [abstract]. Clin Neurol Neurosurg 1985; 81 (1): 66
132. Maggio B, Giampietro L. Su alcuni effetti endocrinologici del VPA. Bollettino della Lega Italiana contro l'Epilessia 1987; 58/59: 205-6
133. Jones TH. Sodium valproate-induced menstrual disturbances in young women. Horm Res 1991; 35 (2): 82-5
134. Tauboll E, Isojarvi JIT, Flinstad Harbo H, et al. Changes in sex-steroid hormone levels and ovarian structure after valproate treatment in female rats [abstract]. Epilepsia 1997; 38 Suppl. 8: 47
135. Tauboll E, Berner A, Gjerstad L, et al. Valproate-induced changes in the ovaries are not associated with pathological p53 protein expression in rats [abstract]. Epilepsia 1998; 39 Suppl. 6: 41
136. Tauboll E, Isojarvi JIT, Harbo H, et al. Long-term valproate treatment induces changes in ovarian morphology and serum sex steroid hormone levels in female Wistar rats. Seizure 1999; 8 (8): 490-3
137. Gregoraszczuk E, Wojtowicz A, Tauboll E, et al. Valproate-induced alterations in testosterone, estradiol and progesterone secretion from porcine follicular cells isolated from small- and medium-sized ovarian follicles. Seizure 2000; 9 (7): 480-5
138. Roste L, Tauboll E, Berner A, et al. Valproate, but not lamotrigine, induces ovarian morphological changes in Wistar rats. Exp Toxicol Pathol 2001; 52 (6): 545-52
139. Gregoraszczuk E, Wojtowicz A, Tauboll E, et al. Valproate alters secretion of peripheral sex steroid hormones from porcine ovarian follicular cells [abstract]. Epilepsia 2001; 42 Suppl. 2: 36-7
140. Korytkowski M, Mokan M, Horwitz M, et al. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1995; 80: 3327-34
141. Steppan C, Lazar M. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab 2002; 13 1: 18-23
142. Sievenpiper JL, Jenkins AL, Whitham DL, et al. Insulin resistance: concepts, controversies, and the role of nutrition. Can J Diet Pract Res 2002; 63: 20-32
143. Matthaei S, Stumvoll M, Kellerer M, et al. Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev 2000; 21 (6): 585-618
144. Kahn B, Flier J. Obesity and insulin resistance. J Clin Invest 2000; 106: 473-81
145. Fox R, Corrigan E, Thoma P, et al. The diagnosis of polycystic ovaries in women with oligo-amenorrhea: predictive power of endocrine tests. Clin Endocrinol 1991; 34: 127-31
146. Rasgon N. Investigating polycystic ovary syndrome in women with bipolar disorder. Psychiatric Times 2001; XVIII: 5
147. American Institute of Ultrasound in Medicine. Guidelines for performance of ultrasound examination of the female pelvis. Laurel (MD): American Institute of Ultrasound in Medicine, 1995
148. Faur N, Prat X, Bastide A, et al. Assessment of ovaries by magnetic resonance imaging in patients presenting with polycystic ovarian syndrome. Hum Reprod 1989; 4: 468-72
149. Kimura I, Togashi K, Kawakami S, et al. Polycystic ovaries: implications of diagnosis with MR imaging. Radiology 1996; 201 (2): 549-52
150. Herzog AG. A relationship between particular reproductive endocrine disorders and the laterality of epileptiform discharges in women with epilepsy. Neurology 1993; 43: 1907-10
151. Skierska E, Leszczynska-Bystrzanowska J, Gajewski AK. Risk analysis of menstrual disorders in young women from urban population. Przegl Epidemiol 1996; 50: 467-74
152. Laidlaw J. Catamenial epilepsy. Lancet 1956; II: 1235-7
153. Logothetis J, Harner R, Morrell F, et al. The role of estrogens in catamenial exacerbations of epilepsy. Neurology 1959; 9: 352-60
154. Trampuz V, Dimitrijevic M, Kryzanovski J. Ulga epilepsije u patogenezi disfunkcije ovarija. Neuropsihijatrija 1975; 23: 179-83
155. Backstrom T. Epileptic seizures in women related to plasma estrogen and progesterone during the menstrual cycle. Acta Neurol Scand 1976; 54: 321-47
156. Rosciszewska D, Dudkiewicz J, Blecharz A. Changes in cytohormonal cervical swabs in epileptic women. Neurol Neurochir Pol 1976; 10: 255-9
157. Jensen I, Vaernet K. Temporal lobe epilepsy: follow-up investigation of 74 temporal lobe resected patients. Acta Neurochir 1977; 37: 173-200
158. Mattson RH, Kamer JA, Caldwell BV, et al. Seizure frequency and the menstrual cycle: a clinical study [abstract]. Epilepsia 1981; 22: 242
159. Egger J, Brett E. Effects of sodium valproate in 100 children with special reference to weight. BMJ (Clin Res Ed) 1981; 283 (6291): 577-81
160. Novak G, Maytal J, Alshansky A, et al. Risk of excessive weight gain in epileptic children treated with valproate. J Child Neurol 1999; 14 (8): 490-5
161. Demir E, Aysun S. Weight gain associated with valproate in childhood. Pediatr Neurol 2000; 22 (5): 361-4
162. Dinesen H, Gram L, Andersen T, et al. Weight gain during treatment with valproate. Acta Neurol Scand 1984; 70 (2): 65-9
163. Corman C, Leung N, Guberman A. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci 1997; 24 (3): 240-4
164. Verrotti A, Basciani F, Morresi S, et al. Serum leptin changes in patients who gain weight after therapy with valproic acid. Neurology 1999; 53 (1): 230-2
165. Biton V, Mirza W, Montouris G, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001; 56 (2): 172-7
166. Jallon P, Picard F. Body weight gain and anticonvulsants: a comparative review. Drug Saf 2001; 24 (13): 969-78
167. Morales AJ, Laughlin GA, Butzow T, et al. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab 1996; 81: 2854-64
168. Pasquali R, Antenucci D, Casimirri F, et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989; 68: 173-9